Results for tag: "Tivozanib"

Tivozanib is a type of kidney cancer drug used to treat advanced renal cell carcinoma (RCC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Tivozanib is typically used in combination with other drugs to treat RCC. It is taken orally once daily and is usually taken for up to 12 weeks. Common side effects of tivozanib include fatigue, nausea, diarrhea, and decreased appetite. Tivozanib is a relatively new drug in the kidney cancer market, having been approved by the US Food and Drug Administration (FDA) in 2013. It is the only TKI approved for the treatment of advanced RCC in the United States. It is also approved in the European Union and other countries. Several companies are involved in the tivozanib market, including Astellas Pharma, Inc., which manufactures and markets the drug in the United States; EUSA Pharma, which markets the drug in Europe; and Aveo Pharmaceuticals, which developed the drug. Other companies involved in the market include Daiichi Sankyo, Inc., which holds the rights to the drug in Japan, and Teva Pharmaceuticals, which holds the rights to the drug in Canada. Show Less Read more